Anlotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Anlotinib
Accession Number
DB11885
Type
Small Molecule
Groups
Investigational
Description

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
AL 3818 / AL-3818 / AL3818
Categories
UNII
GKF8S4C432
CAS number
1058156-90-3
Weight
Average: 407.445
Monoisotopic: 407.164519743
Chemical Formula
C23H22FN3O3
InChI Key
KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
IUPAC Name
1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine
SMILES
COC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
25017411
PubChem Substance
347828221
ChemSpider
45743493

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMalignancies1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentCancer, Advanced2
1Not Yet RecruitingTreatmentAdvanced Solid Tumors1
1Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Not Yet RecruitingTreatmentLung Cancers1
1, 2Not Yet RecruitingTreatmentAdvanced Acral Malignant Melanoma1
1, 2Not Yet RecruitingTreatmentAdvanced Cholangiocarcinoma1
1, 2Not Yet RecruitingTreatmentLung Cancer Metastatic1
1, 2Not Yet RecruitingTreatmentLung Cancers1
1, 2RecruitingPreventionHepatocellular,Carcinoma1
1, 2RecruitingTreatmentCervical Carcinoma / Endometrial Carcinoma / Fallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentEwing's Tumor Metastatic1
1, 2RecruitingTreatmentRecurrent Glioblastoma1
1, 2TerminatedTreatmentCancer of the Ovary / Cervical Cancers / Endometrial Cancers1
2Active Not RecruitingTreatmentAnlotinib / RCC1
2Active Not RecruitingTreatmentNeoplasm of Bone1
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentMalignancies1
2CompletedTreatmentSquamous Cell Carcinoma of Esophagus1
2CompletedTreatmentTumors1
2Not Yet RecruitingTreatmentAdenocarcinomas / Distantly Metastatic Malignant Neoplasm / Head and Neck Carcinoma / Recurrent Disease1
2Not Yet RecruitingTreatmentCarcinoma NOS / Lung Cancer Small Cell Lung Cancer (SCLC) / Neoplasms, Lung1
2Not Yet RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Not Yet RecruitingTreatmentNasopharyngeal Carcinoma1
2Not Yet RecruitingTreatmentSmall Cell Lung Carcinoma1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS) / Undifferentiated Pleomorphic Sarcoma1
2RecruitingTreatmentAnlotinib / Antineoplastic Agents / Neoplasms, Breast1
2RecruitingTreatmentAnlotinib / Early Stage / Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type / Open / Peg-aspargase / Phase Two / Single Center / Sintilimab1
2RecruitingTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2RecruitingTreatmentEGFR Gene Mutations1
2RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer1
2RecruitingTreatmentGastroenteropancreatic Neuroendocrine Tumor G31
2RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type2
2RecruitingTreatmentNon-driver Mutation Advanced Non-Squamous Non Small Cell Lung Cancer / Non-Squamous Non Small Cell Lung Cancer1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)2
2RecruitingTreatmentRefractory Small cell lung cancer1
2, 3Active Not RecruitingBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
2, 3Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2, 3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3CompletedTreatmentMedullary Thyroid Cancer (MTC)1
2, 3CompletedTreatmentMetastatic Colorectal Cancers1
2, 3RecruitingTreatmentAdvanced Solid Tumors1
2, 3RecruitingTreatmentMalignant Neoplasm of Stomach1
3RecruitingTreatmentAlveolar Soft Part Sarcoma (ASPS) / Leiomyosarcomas / Soft-Tissue Sarcoma / Synovial Sarcoma1
4Not Yet RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
4Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentCancer of Liver1
Not AvailableNot Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer3
Not AvailableRecruitingTreatmentAdvanced Solid Tumors1
Not AvailableRecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00238 mg/mLALOGPS
logP3.7ALOGPS
logP3.35ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)16.65ChemAxon
pKa (Strongest Basic)9.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.39 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.65 m3·mol-1ChemAxon
Polarizability42.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Diarylethers
Alternative Parents
Quinolines and derivatives / Indoles / Anisoles / Alkyl aryl ethers / Substituted pyrroles / Pyridines and derivatives / Aryl fluorides / Heteroaromatic compounds / Azacyclic compounds / Organofluorides
show 2 more
Substituents
Diaryl ether / Quinoline / Indole / Indole or derivatives / Anisole / Phenol ether / Alkyl aryl ether / Aryl fluoride / Aryl halide / Benzenoid
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:57 / Updated on June 04, 2019 07:28